Summary
Vertex Pharmaceuticals Inc. reported a significant net loss for the three and six months ended June 30, 2014, primarily driven by high research and development expenses. Total revenues declined substantially year-over-year, largely due to a sharp decrease in INCIVEK product revenues, though this was partially offset by growth in KALYDECO net product revenues. The company has made progress on its key pipeline drug, lumacaftor in combination with ivacaftor, with positive Phase 3 trial data and plans to submit for regulatory approval. Despite the current net loss, Vertex Pharmaceuticals maintains a substantial cash position, bolstered by a recent $300 million term loan, which is expected to fund operations for at least the next twelve months. Investor focus should be on the upcoming regulatory submission for lumacaftor/ivacaftor, which represents the company's primary growth driver. The company's ability to navigate the approval process and subsequent market penetration will be critical for future profitability. Continued growth in KALYDECO sales and effective management of R&D spending are also key areas to monitor.
Financial Highlights
48 data points| Revenue | $138.42M |
| Cost of Revenue | $9.65M |
| Gross Profit | $128.77M |
| R&D Expenses | $224.49M |
| SG&A Expenses | $77.45M |
| Operating Expenses | $318.96M |
| Operating Income | -$180.54M |
| Net Income | -$159.38M |
| EPS (Basic) | $-0.68 |
| EPS (Diluted) | $-0.68 |
| Shares Outstanding (Basic) | 233.81M |
| Shares Outstanding (Diluted) | 233.81M |
Key Highlights
- 1Net loss attributable to Vertex was $159.4 million for Q2 2014, a significant increase from a $57.2 million loss in Q2 2013.
- 2Total revenues decreased by 55% year-over-year to $138.4 million in Q2 2014, primarily due to a steep decline in INCIVEK sales.
- 3KALYDECO product revenues showed strong growth, increasing by 14% year-over-year in Q2 2014 to $113.1 million.
- 4The company announced positive Phase 3 trial results for lumacaftor in combination with ivacaftor and plans to submit for regulatory approval in Q4 2014.
- 5Research and development expenses remained high, totaling $224.8 million in Q2 2014, a slight increase of 1% year-over-year.
- 6Vertex Pharmaceuticals secured a $300 million senior secured term loan in July 2014, providing a significant liquidity boost.
- 7The company's cash, cash equivalents, and marketable securities stood at $1.22 billion as of June 30, 2014.